NLS Pharmaceutics (NLSP)’ merger partner Kadimastem has been granted a patent by the Hong Kong Intellectual Property Department covering Kadimastem’s proprietary cell selection and enrichment technology used in the development of IsletRx, a stem cell-derived therapy candidate intended to treat-and potentially cure-insulin-dependent diabetes. According to Kadimastem, the Hong Kong patent adds to previously granted patents in Europe, the United States and India, further strengthening the global protection around IsletRx. The patented process enables the selection and enrichment of highly functional islet cells from differentiated cell populations to help maximize therapeutic effect.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NLSP:
- NLS Pharmaceutics Extends Merger Agreement with Kadimastem
- NLS Pharmaceutics Reschedules Shareholders’ Meeting Amid SEC Review
- NLS Pharmaceutics Enters Warrant Exchange Agreement with Alpha Capital
- NLS Pharmaceutics Amends Merger Agreement with Kadimastem
- NLS Pharmaceutics Advances iTOL-102 Diabetes Program with BIRD Foundation Support